Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Total Non-Current Liabilities (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 434.67% to $2.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, up 434.67% year-over-year, with the annual reading at $2.0 billion for FY2025, 434.67% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $2.0 billion at BeOne Medicines, up from $1.1 billion in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $2.0 billion in Q4 2025, with the low at $318.1 million in Q2 2025.
  • Average Total Non-Current Liabilities over 5 years is $641.2 million, with a median of $536.2 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities tumbled 34.35% in 2022, then surged 434.67% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $803.4 million in 2021, then tumbled by 34.35% to $527.4 million in 2022, then dropped by 13.19% to $457.8 million in 2023, then fell by 18.36% to $373.8 million in 2024, then soared by 434.67% to $2.0 billion in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $2.0 billion, $1.1 billion, and $318.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.